NCT06323265招募中不适用
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Hebei Medical University Fourth Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年3月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age:≥18 years old;
- •Patients with extensive stage small cell lung cancer confirmed by histopathology;
- •Normal function of major organs;
- •Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
排除标准
- •Patients with drug allergy sufferers;
- •Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc;
- •History of psychiatric drugs abuse and can't quit or patients with mental disorders;
- •The researchers think inappropriate.
研究组 & 干预措施
Experimental
干预措施: Adebrelimab + chemotherapy (Drug)
Experimental
干预措施: ±chest radiotherapy (Radiation)
结局指标
主要结局
Progression free survival (PFS)
时间窗: evaluated in 24 months since the treatment began
Baseline to measured date of progression or death from any cause
次要结局
- Objective response rate (ORR)(tumor assessment every 6 weeks since the treatment began，up to 24 months)
- Disease control rate (DCR)(tumor assessment every 6 weeks since the treatment began，up to 24 months)
- Duration of Overall Response（DoR）(tumor assessment every 6 weeks since the treatment began，up to 24 months)
- Adverse events(up to 24 months)
- Overall survival (OS)(the first day of treatment to death or last survival confirm date,up to 24 months)
研究者
Jun wang
Study Principal Investigator
Hebei Medical University Fourth Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic CancerPancreatic CancerNeoadjuvant TherapyNCT06177522Jinling Hospital, China30
招募中
2 期
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaLocally Advanced or Metastatic Esophageal Squamous Cell CarcinomaNCT06339619Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University32
尚未招募
2 期
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line ImmunotherapyNon-small Cell Lung CancerNCT06182800The First Affiliated Hospital of Xinxiang Medical College35
尚未招募
2 期
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerHR+/HER2- Breast CancerBreast CancerNCT06470633The First Affiliated Hospital with Nanjing Medical University29
招募中
2 期
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerMetastatic Colorectal CancerNCT06231017The First Affiliated Hospital of Zhengzhou University36